CA2250723C - Proteine de fusion a epitopes multiples - Google Patents

Proteine de fusion a epitopes multiples Download PDF

Info

Publication number
CA2250723C
CA2250723C CA2250723A CA2250723A CA2250723C CA 2250723 C CA2250723 C CA 2250723C CA 2250723 A CA2250723 A CA 2250723A CA 2250723 A CA2250723 A CA 2250723A CA 2250723 C CA2250723 C CA 2250723C
Authority
CA
Canada
Prior art keywords
epitope
epitopes
hcv
mefa
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2250723A
Other languages
English (en)
Other versions
CA2250723A1 (fr
Inventor
Pablo D.T. Valenzuela
David Ying Chien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grifols Worldwide Operations Ltd
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/653,226 external-priority patent/US6514731B1/en
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of CA2250723A1 publication Critical patent/CA2250723A1/fr
Application granted granted Critical
Publication of CA2250723C publication Critical patent/CA2250723C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Procédé de fabrication d'immuno-essais à base d'épitopes à copies multiples qui consiste à: 1) identifier les séquences nucléotidiques qui codent plusieurs épitopes différents; 2) placer les séquences nucléotidiques dans une cassette d'expression; au moins deux copies d'une séquence codant pour le même épitope, provenant de préférence de souches différentes d'un pathogène, sont placées dans la cassette; 3) transformer un hôte convenable avec la cassette pour exprimer les séquences codant les épitopes; 4) purifier les épitopes exprimés; et 5) appliquer les épitopes à la surface d'un substrat. Les épitopes purifiés répondent à la formule structurale générale (A)¿x?-(B)¿y?-(C)¿z?, qui représente une séquence linéaire d'acides aminés, où B est une séquence d'acides aminés d'un épitope ou d'un groupement d'épitopes, chaque B comprenant au minimum cinq et au maximum mille acides aminés, où y est un nombre entier égal ou supérieur à 2, où A et C sont indépendamment l'un de l'autre des séquences d'acides aminés d'un épitope ou d'un groupement d'épitopes non adjacents à B de par sa nature, et où x et z sont égaux à 1 ou plus. Les épitopes de la présente invention sont plus solubles que les épitopes conventionnels et peuvent, de ce fait, être purifiés plus facilement. De plus, la présence de séquences répétitives d'épitopes (qui répètent au moins B dans la même séquence linéaire d'acides aminés provenant de souches différentes d'un pathogène) augmente la sensibilité et la spécificité de l'essai. Ladite présence de séquences répétitives d'épitopes dans un antigène linéaire isolé facilite également le masquage et permet d'inclure un nombre plus élevé d'épitopes dans une zone unitaire d'un substrat, ce qui augmente la sensibilité en matière de détection d'anticorps.
CA2250723A 1996-05-24 1997-05-23 Proteine de fusion a epitopes multiples Expired - Lifetime CA2250723C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/653,226 US6514731B1 (en) 1996-05-24 1996-05-24 Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens
US08/653,226 1996-05-24
US08/859,524 US6428792B1 (en) 1996-05-24 1997-05-20 Hepatitis C virus multiple copy epitope fusion antigens
US08/859,524 1997-05-20
PCT/US1997/008950 WO1997044469A2 (fr) 1996-05-24 1997-05-23 Proteine de fusion a epitopes multiples

Publications (2)

Publication Number Publication Date
CA2250723A1 CA2250723A1 (fr) 1997-11-27
CA2250723C true CA2250723C (fr) 2012-07-17

Family

ID=27096474

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2250723A Expired - Lifetime CA2250723C (fr) 1996-05-24 1997-05-23 Proteine de fusion a epitopes multiples

Country Status (11)

Country Link
EP (1) EP0935662B1 (fr)
JP (2) JP3945822B2 (fr)
AT (1) ATE311463T1 (fr)
AU (1) AU719929B2 (fr)
CA (1) CA2250723C (fr)
DE (1) DE69734776T2 (fr)
DK (1) DK0935662T3 (fr)
ES (1) ES2251028T3 (fr)
IL (1) IL126460A (fr)
NZ (1) NZ333431A (fr)
WO (1) WO1997044469A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0870830A3 (fr) * 1997-02-10 2004-02-25 Advanced Life Science Institute, Inc. Antigene chimérique derivé du virus de l'hépatite C
AU9497998A (en) * 1997-09-22 1999-04-12 Chiron Corporation Method for detecting antibodies in a sample
EP1021723B1 (fr) 1997-09-22 2008-12-10 Novartis Vaccines and Diagnostics, Inc. Tampons pour hcv antigenes de stabilisation
EP1056762A4 (fr) * 1998-01-30 2003-07-23 Gen Hospital Corp Immunisation genetique avec des proteines non structurales du virus de l'hepatite c
TR200003024T2 (tr) 1998-04-17 2000-12-21 Innogenetics N.V. İndirgeme ajanlarını kullanarak geliştirilen immünodiagnostik tahliller.
AU3714499A (en) * 1998-05-14 1999-11-29 Pasteur Merieux Serums Et Vaccins Hepatitis c virus mimotopes
US7052696B2 (en) * 1998-07-10 2006-05-30 The United States Of America As Represented By The Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
US6379903B1 (en) * 1999-10-08 2002-04-30 Sigma-Aldrich Co. Purification of recombinant proteins fused to multiple epitopes
US6562346B1 (en) 1999-10-27 2003-05-13 Chiron Corporation Activation of HCV-specific T cells
BR0017052B1 (pt) * 1999-12-28 2013-12-24 Epimmune Inc Método para a projeção de um constructo poliepitópico e constructo poliepitópico preparado pelo referido método
EP1829891B1 (fr) 2000-06-15 2012-12-26 Novartis Vaccines and Diagnostics, Inc. Immunoessais pour anticorps anti-VHC
EP1350105B1 (fr) 2000-06-15 2007-07-25 Novartis Vaccines and Diagnostics, Inc. Dosages immunologiques pour anticorps anti-vhc
US7491808B2 (en) 2000-06-15 2009-02-17 Novartis Vaccines And Diagnostics, Inc. HCV non-structural protein mutants and uses thereof
WO2003008537A2 (fr) * 2001-04-06 2003-01-30 Mannkind Corporation Sequences d'epitope
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
NZ538711A (en) 2002-09-09 2007-01-26 Chiron Corp Antigen/antibody/antigen sandwich assays for detecting hepatitis C virus infections
AU2003287188A1 (en) * 2002-10-25 2004-05-25 Chiron Corporation Activation of hcv-specific cells
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
JP4836281B2 (ja) 2004-08-27 2011-12-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド Ｈｃｖ非構造タンパク質変異体およびその使用
ES2948791T3 (es) * 2005-06-17 2023-09-19 Msd Italia Srl Vacuna de ácido nucleico contra el virus de la hepatitis C
EP2360175B1 (fr) 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Particules de type virus (vlps) de norovirus et de sapovirus
US8815253B2 (en) 2007-12-07 2014-08-26 Novartis Ag Compositions for inducing immune responses
CN103282375B (zh) 2010-12-02 2017-01-11 比奥诺尔免疫有限公司 肽支架设计
MX346475B (es) 2011-01-06 2017-03-22 Bionor Immuno As Peptidos inmunogenicos monomericos y multimericos.
CN104203272A (zh) * 2012-01-26 2014-12-10 长角牛疫苗和诊断有限责任公司 复合抗原序列及疫苗
MX2014014683A (es) 2012-06-06 2015-02-24 Bionor Immuno As Peptidos derivados de proteinas virales para usarse como inmunogenos y reactivos de dosificacion.
US11867696B2 (en) 2015-02-06 2024-01-09 Cell Idx, Inc. Antigen-coupled immunoreagents
DK3274478T3 (da) 2015-03-27 2020-11-23 Ortho Clinical Diagnostics K K Hcv-ns4a/modificerede ns3-polypeptider og anvendelser deraf
WO2018017606A1 (fr) * 2016-07-18 2018-01-25 Cell Idx, Inc. Réactifs d'hybridation couplés à un antigène
KR101813586B1 (ko) * 2016-12-29 2018-01-30 고려대학교 산학협력단 다양한 질병마커 인지 에피토프와 연결된 단백질 나노입자 및 이를 이용한 고민감도 질병마커 검출방법
JP7389740B2 (ja) * 2017-07-27 2023-11-30 エフ． ホフマン－ラ ロシュ アーゲー Ｈｃｖ抗原のマルチエピトープ融合タンパク質およびその使用
KR101871985B1 (ko) * 2017-08-14 2018-06-27 고려대학교 산학협력단 3차원 단백질 나노입자 프로브 기반 복수 질환의 동시검출 방법 및 키트
CN108794636B (zh) * 2018-06-28 2020-05-22 中国人民解放军军事科学院军事医学研究院 一种表位多肽串联混合物在抗立氏立克次体的免疫保护中的应用
KR102100813B1 (ko) * 2018-11-08 2020-04-16 주식회사 보레다바이오텍 C형 간염바이러스 유래 융합 단백질 및 이를 포함하는 진단키트

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA40572C2 (uk) * 1991-06-24 2001-08-15 Чірон Корпорейшн Поліпептид, що містить укорочену послідовність вірусу гепатиту с, ізольований епітоп, реагент для імуноаналізу на вірус гепатиту с (варіанти), спосіб виявлення наявності антитіл (варіанти)
PT100978B (pt) * 1991-10-16 1999-10-29 Immulogic Pharma Corp Peptidos recombitope, sequencias de acidos nucleicos que os codificam, composicoes terapeuticas que os contem, processo para a sua concepcao e sue uso.
US5683695A (en) * 1993-02-10 1997-11-04 United Biomedical, Inc. Production of recombinant proteins containing multiple antigenic determinants linked by flexible hinge domains
US5744144A (en) * 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
GB2294047A (en) * 1994-10-14 1996-04-17 Merck & Co Inc Synthetic peptides for use as epitopes specific for HIV

Also Published As

Publication number Publication date
DE69734776D1 (de) 2006-02-09
WO1997044469A3 (fr) 1997-12-31
WO1997044469A8 (fr) 1999-07-22
JP2007127671A (ja) 2007-05-24
WO1997044469A2 (fr) 1997-11-27
EP0935662B1 (fr) 2005-11-30
IL126460A0 (en) 1999-08-17
DK0935662T3 (da) 2006-03-06
ES2251028T3 (es) 2006-04-16
IL126460A (en) 2007-07-04
AU3214397A (en) 1997-12-09
AU719929B2 (en) 2000-05-18
NZ333431A (en) 2000-05-26
DE69734776T2 (de) 2006-08-17
JP2001500723A (ja) 2001-01-23
JP3945822B2 (ja) 2007-07-18
ATE311463T1 (de) 2005-12-15
CA2250723A1 (fr) 1997-11-27
EP0935662A2 (fr) 1999-08-18

Similar Documents

Publication Publication Date Title
CA2250723C (fr) Proteine de fusion a epitopes multiples
US6428792B1 (en) Hepatitis C virus multiple copy epitope fusion antigens
US6596476B1 (en) Hepatitis C assay
ES2134388T5 (es) Combinaciones de antigenos del virus de la hepatitis c (hcv) para su uso en inmunoensayos para anticuerpos anti-hcv.
US6312889B1 (en) Combinations of hepatitis c virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US5683864A (en) Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
JP4427182B2 (ja) 抗原を安定化するための緩衝液
JP3188717B2 (ja) Ｃ型肝炎アッセイ
US6727092B2 (en) Methods for the simultaneous detection of HCV antigens and HCV antibodies
EP0472207B1 (fr) Essai d'hépatite C utilisant des antigènes recombinants
EP0642666B1 (fr) Analyse de detection de l'hepatite c
US20040185436A1 (en) Methods for the simultaneous detection of HCV antigens and HCV antibodies
JP5070055B2 (ja) 改変タンパク分解性切断部位を有するｈｃｖ多エピトープ融合抗原およびその使用
Wienhues et al. Characterization of a linear epitope in the nonstructural region 4 of hepatitis C virus with reactivity to seroconversion antibodies
JP3327549B2 (ja) Ｃ１００領域に対する組換え抗原を利用したｃ型肝炎アッセイ
Peng et al. Expression and immunoreactivity of an epitope of HCV in a foreign epitope presenting system
CA2082924A1 (fr) Immunoessai pour le diagnostic de l'hepatite non-a non-b.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20170523